A structure/activity relationship study on arvanil, an endocannabinoid and vanilloid hybrid

Area of Science:

• Pharmacology
• Neuroscience
• Medicinal Chemistry

Background:

• Arvanil is a hybrid molecule targeting cannabinoid receptor 1 (CB1) and capsaicin receptor VR1.
• Arvanil inhibits the anandamide membrane transporter (AMT) and induces cannabimimetic effects.

Purpose of the Study:

• To synthesize and evaluate novel arvanil derivatives.
• To investigate their activity at CB1, VR1, AMT, and fatty acid amide hydrolase (FAAH).
• To determine their ability to produce cannabimimetic effects in mice.

Main Methods:

• Synthesis of arvanil derivatives with modifications (N-methylation, urea/thiourea, vanillyl group).
• In vitro assays for CB1 binding/activation, VR1 activation, AMT inhibition, and FAAH inhibition.
• In vivo assessment of cannabimimetic effects in mice (mouse tetrad).

Main Results:

• Arvanil derivatives did not stimulate CB1 receptors.
• Modifications affected VR1, AMT, and FAAH activities; some decreased VR1/AMT activity but increased FAAH inhibition.
• Urea analog was a potent FAAH inhibitor; O-2142 showed potent VR1 activity and FAAH inhibition.
• Compound O-2093, despite lacking VR1/CB1 activity, was the most potent in vivo.

Conclusions:

• Cannabimimetic responses in mice can be mediated by VR1 or other uncharacterized receptors.
• Structural modifications of arvanil can decouple VR1/CB1 activity from in vivo effects.
• Arvanil derivatives offer potential for developing novel therapeutic agents targeting pain and other conditions.